

Surgical Innovations Group plc (AIM:SUN), a leading creator of innovative medical technology to address unmet clinical needs in minimally invasive surgery ('MIS'), will hold its Annual General Meeting at 2.00pm today at Clayton Wood House, 6 Clayton Wood Bank, Leeds, LS16 6QZ, during which the Chairman, Doug Liversidge CBE, will make the following statement:

"The Board is pleased that the Company is now succeeding in capitalising on the infrastructure put in place over the past year. We are confident that our investment choices and strategic decisions will result in future growth. Working capital has been significantly enhanced following the investment from Chris Rea, as announced on 9 June 2014 which will support the development, together with promotion, of our unique clinical solution for 3mm surgery. We look forward to welcoming Chris to the Board.

"We continue to build upon last year's strong growth both in the UK and US. The Resposable® concept provides a cost-saving solution to the NHS which is committed to cost reduction programs in UK hospitals. During 2013, there was a 59% increase in the number of Yorkshire hospitals using SI branded products. The US remains a key market and the Company is effectively broadening sales channels in order to realise revenue and brand recognition opportunities. This is evidenced by the 75% increase in sales to the US of SI branded products driven primarily by new dealer relationships across the US.

"The Board is committed to improving our manufacturing capabilities to effectively satisfy the global demand for both SI branded and OEM products. The Group is satisfied that in recent months our continued investment is being realised in this area as significant improvements have been made.

"The product development pipeline continues to be strengthened through the focused investment in our 3mm 'Ultra MIS' technology, underpinned by our allegiances with Key Opinion Leaders in this specific surgical field. The Board is confident that the Group's future success will be achieved through the strategic introduction of our '3mm 'Ultra MIS' clinical solutions.

"Overall, we are pleased with the progress made and look to the future with confidence."